Các tế bào basophil và mast trong chứng mày đay tự phát mạn tính

Kaplan AP: Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004, 114:465–474; quiz 75. Excellent review of current clinical treatments and autoantibody theory in CIU. Kaplan AP: Clinical practice: chronic urticaria and angioedema. N Engl J Med 2002, 346:175–179. Toubi E, Kessel A, Avshovich N, et al.: Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004, 59:869–873. Prospective study of clinical features in CIU related to disease duration. Federman DG, Kirsner RS, Moriarty JP, Concato J: The effect of antibiotic therapy for patients infected with Helicobacter pylori who have chronic urticaria. J Am Acad Dermatol 2003, 49:861–864. Wedi B, Raap U, Kapp A: Chronic urticaria and infections. Curr Opin Allergy Clin Immunol 2004, 4:387–396. Grattan CE, O’Donnell BF, Francis DM, et al.: Randomized double-blind study of cyclosporin in chronic "idiopathic" urticaria. Br J Dermatol 2000, 143:365–372. Beck L, Marcotte G, MacGlashan J, et al.: Omalizumab induced reductions in mast cell FceRI expression and function. J Allergy Clin Immunol 2004, 114:527–530. Tong LJ, Balakrishnan G, Kochan JP, et al.: Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 1997, 99:461–465. Ferrer M, Kinet JP, Kaplan AP: Comparative studies of functional and binding assays for IgG anti-Fc(epsilon)RIalpha (alpha-subunit) in chronic urticaria. J Allergy Clin Immunol 1998, 101:672–676. Gruber BL, Baeza ML, Marchese MJ, et al.: Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988, 90:213–217. Hide M, Francis DM, Grattan CE, et al.: Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993, 328:1599–1604. Grattan CE, Francis DM, Slater NG, et al.: Plasmapheresis for severe, unremitting, chronic urticaria. Lancet 1992, 339:1078–1080. Kikuchi Y, Kaplan AP: Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 2001, 107:1056–1062. Kikuchi Y, Kaplan AP: A role for C5a in augmenting IgGdependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002, 109:114–118. Niimi N, Francis DM, Kermani F, et al.: Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 1996, 106:1001–1006. Schulman ES, Kagey-Sobotka A, MacGlashan DW Jr, et al.: Heterogeneity of human mast cells. J Immunol 1983, 131:1936–1941. Sabroe RA, Fiebiger E, Francis DM, et al.: Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol 2002, 110:492–499. Insight into relationship between serologic factors and CIU disease severity. Saini SS, Richardson JJ, Wofsy C, et al.: Expression and modulation of FcepsilonRIalpha and FcepsilonRIbeta in human blood basophils. J Allergy Clin Immunol 2001, 107:832–841. Fiebiger E, Hammerschmid F, Stingl G, Maurer D: Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest 1998, 101:243–251. Miescher SM, Horn MP, Pachlopnik JM, et al.: Natural anti-FcepsilonRIalpha autoantibodies isolated from healthy donors and chronic idiopathic urticaria patients reveal a restricted repertoire and autoreactivity on human basophils. Hum Antibodies 2001, 10:119–126. Sabroe RA, Poon E, Orchard GE, et al.: Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Allergy Clin Immunol 1999, 103:484–493. Sabroe RA, Seed PT, Francis DM, et al.: Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Am Acad Dermatol 1999, 40:443–450. Grattan CE: Basophils in chronic urticaria. J Investig Dermatol Symp Proc 2001, 6:139–140. Grattan CE, Walpole D, Francis DM, et al.: Flow cytometric analysis of basophil numbers in chronic urticaria: basopenia is related to serum histamine releasing activity. Clin Exp Allergy 1997, 27:1417–1424. Kern F, Lichtenstein LM: Defective histamine release in chronic urticaria. J Clin Invest 1976, 57:1369–1377. Grattan CE, Dawn G, Gibbs S, Francis DM: Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy 2003, 33:337–341. Sabroe RA, Francis DM, Barr RM, et al.: Anti-Fc(episilon)RI auto antibodies and basophil histamine releasability in chronic idiopathic urticaria. J Allergy Clin Immunol 1998, 102:651–658. Schleimer RP: Glucocorticosteroids: their mechanism of action and use in allergic diseases. In Allergy Principles and Practice, edn 4. Edited by Middleton E, Reed CE, Ellis EF, et al. St. Louis, MO: Mosby; 1993:893–925. Charlesworth EN, Kagey-Sobotka A, Schleimer RP, et al.: Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. J Immunol 1991, 146:671–676. Yoshimura C, Miyamasu M, Nagase H, et al.: Glucocorticoids induce basophil apoptosis. J Allergy Clin Immunol 2001, 108:215–220. Ying S, Kikuchi Y, Meng Q, et al.: TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002, 109:694–700. Recent study defining characteristics of cellular infiltrate in CIU. Caproni M, Volpi W, Macchia D, et al.: Infiltrating cells and related cytokines in lesional skin of patients with chronic idiopathic urticaria and positive autologous serum skin test. Exp Dermatol 2003, 12:621–628. Smith CH, Kepley C, Schwartz LB, Lee TH: Mast cell number and phenotype in chronic idiopathic urticaria. J Allergy Clin Immunol 1995, 96:360–364. Caproni M, Giomi B, Volpi W, et al.: Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. Clin Immunol 2005, 114:284–292. Schwartz LB, Sakai K, Bradford TR, et al.: The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 1995, 96:2702–2710. Asero R, Tedeschi A, Lorini M, et al.: Circulating stem cell factor in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2003, 91:79–81. Kaplan AP, Garofalo J, Sigler R, Hauber T: Idiopathic cold urticaria: in vitro demonstration of histamine release upon challenge of skin biopsies. N Engl J Med 1981, 305:1074–1077. Irani AA, Schechter NM, Craig SS, et al.: Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci U S A 1986, 83:4464–4468. Jacques P, Lavoie A, Bedard PM, et al.: Chronic idiopathic urticaria: profiles of skin mast cell histamine release during active disease and remission. J Allergy Clin Immunol 1992, 89:1139–1143. Leung DY: Infection in atopic dermatitis. Curr Opin Pediatr 2003, 15:399–404. Supajatura V, Ushio H, Nakao A, et al.: Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 2002, 109:1351–1359. Marshall JS, McCurdy JD, Olynych T: Toll-like receptor-mediated activation of mast cells: implications for allergic disease? Int Arch Allergy Immunol 2003, 132:87–97. Varadaradjalou S, Feger F, Thieblemont N, et al.: Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol 2003, 33:899–906. Tkaczyk C, Okayama Y, Metcalfe DD, Gilfillan AM: Fcgamma receptors on mast cells: activatory and inhibitory regulation of mediator release. Int Arch Allergy Immunol 2004, 133:305–315. Blank U, Rivera J: The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol 2004, 25:266–273. Conroy MC, Adkinson NF Jr, Lichtenstein LM: Measurement of IgE on human basophils: relation to serum IgE and anti-IgEinduced histamine release. J Immunol 1977, 118:1317–1321. Findlay SR, Lichtenstein LM: Basophil releasability in patients with asthma. Am Rev Respir Dis 1980, 122:53–59. Kepley CL, Youssef L, Andrews RP, et al.: Syk deficiency in nonreleaser basophils. J Allergy Clin Immunol 1999, 104:279–284. Lavens-Phillip S, MacGlashan D: The tyrosine kinases, p53 lyn, p72 syk are differentially expressed at the protein level, not the mRNA level in non-releasing human basophils. Am J Cell Respir Mol Med 2000, 23:566–571. Kepley CL, Cohen N: Evidence for human mast cell nonreleaser phenotype. J Allergy Clin Immunol 2003, 112:457–459. Huber M, Helgason CD, Damen JE, et al.: The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation. Proc Natl Acad Sci U S A 1998, 95:11330–11335. Rauh MJ, Krystal G: Of mice and men: elucidating the role of SH2-containing inositol 5-phosphatase (SHIP) in human disease. Clin Invest Med 2002, 25:68–70. Excellent review of the clinical implications of SHIP phosphatase activity in human disease. MacDonald SM, Rafnar T, Langdon J, Lichtenstein LM: Molecular identification of an IgE-dependent histamine-releasing factor. Science 1995, 269:688–690. Vonakis BM, Gibbons S Jr, Sora R, et al.: Src homology 2 domain-containing inositol 5’ phosphatase is negatively associated with histamine release to human recombinant histamine-releasing factor in human basophils. J Allergy Clin Immunol 2001, 108:822–831. Clement S, Krause U, Desmedt F, et al.: The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 2001, 409:92–97. Marion E, Kaisaki PJ, Pouillon V, et al.: The gene INPPL1, encoding the lipid phosphatase SHIP2, is a candidate for type 2 diabetes in rat and man. Diabetes 2002, 51:2012–2017. Saini SS, Vasagar K, Huang F, et al.: Signaling defects in basophils in chronic urticaria. J Allergy Clin Immunol 2003, 111:S178.